Please don't take your organs to heaven,heaven knows we need them here
Followers | 517 |
Posts | 102,285 |
Boards Moderated | 2 |
Alias Born | 01/18/2003 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thx ya kinda figured that...
guess I is in..all I seen was email addy and password...guess that was for nascar cuz already a member there i guess cuz they had them both didnt see anyplace for hubnutz and diehard..
Mornin All~~!!
were both kinda lost on how this works..guess we is old and senile loll...dont get that part about swapping out at sometime in the race and putting someone else in his place and garage picks hope to figure it out soon...maybe another recap bout scoring and all that good chit would help thx eli and all..cuz we is lost..brain farts here
Mornin All~~!!
8-19-23
Mornin All~~!!
BWVI NEWS:Psycheceutical Bioscience Inc BWVI:OTC Pink - Current Information
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
GlobeNewswire
10:20 AM ET
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSDCompany intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSDGlobeNewswireFebruary 02, 2023MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, is pleased to announce it has completed its pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration (FDA) and received positive feedback regarding the Company's development plans for a novel NeuroDirect(TM) topical formulation of ketamine, intended for treating post-traumatic stress disorder (PTSD).
The FDA has given guidance to Psycheceutical regarding its development plans for preclinical studies required for an IND submission and the design of related Phase I and II clinical studies. In 2023, Psycheceutical remains focused on completing the remaining IND-enabling studies that will support the IND submission and transition into Phase I and Phase II clinical studies.
"We are undergoing a mental health epidemic, with millions suffering from conditions like PTSD with no current therapeutics on the market to help. We believe that NeuroDirect(TM) ketamine has the potential to be a life-altering treatment option that will provide profound benefits and relief to patients suffering from PTSD," said Chad Harman, CEO of Psycheceutical. "We thank the FDA for the constructive guidance during our pre-IND meeting. The constructive feedback and direction will allow us to be efficient and systematic towards safely transitioning our novel topical treatment from preclinical studies into a full clinical evaluation."
In written responses to the questions provided by Psycheceutical, the FDA provided guidance on inquiries related to manufacturing, safety/toxicology, pre-clinical efficacy studies, clinical trial design, and the rationale necessary to support subsequent human clinical trials. This feedback supports Psycheceutical with greater clarity on the current requirements needed to file an acceptable IND to initiate Phase I and II clinical trials of NeuroDirect(TM) ketamine.Based upon the historical clinical data for ketamine and the C ompany's preclinical testing planned for NeuroDirect(TM) ketamine in 2023, the Company anticipates filing an IND by the end of 2023. In addition, Psycheceutical intends to pursue accelerated approval through one of the FDA's expedited drug approval programs, such as Breakthrough Therapy, pending the development of preliminary clinical evidence to support such designation.
NeuroDirect(TM) for Non-Systemic DeliveryPsycheceutical's patented NeuroDirect(TM) non-systemic delivery technology is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results, while avoiding the systemic side effects of psychedelic compounds suc h as hallucinations, nausea, vomiting, and toxicity. NeuroDirect(TM) is designed to be administered through telehealth or at home instead of a clinical setting, greatly lowering the cost of care for each patient, ensuring that these life-saving treatments are cheap and available to anyone suffering from mental health disorders or central nervous system diseases.
About Psycheceutical Bioscience, Inc. Psycheceutical Bioscience, Inc. is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and top minds in the psychedelic space, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to any one suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
Forward-Looking Statements:Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availab ility and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," "may," "should," "could," "intend," "estimate," "plan," "anticipate," "expect," "believe," "potential" or "continue," or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
Kaia Roman, VP, Strategy & Communications kaia.roman@psycheceutical.com
NEWS: Psycheceutical Bioscience Inc BWVI:OTC Pink - Current Information
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
GlobeNewswire
10:20 AM ET
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSDCompany intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSDGlobeNewswireFebruary 02, 2023MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, is pleased to announce it has completed its pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration (FDA) and received positive feedback regarding the Company's development plans for a novel NeuroDirect(TM) topical formulation of ketamine, intended for treating post-traumatic stress disorder (PTSD).
The FDA has given guidance to Psycheceutical regarding its development plans for preclinical studies required for an IND submission and the design of related Phase I and II clinical studies. In 2023, Psycheceutical remains focused on completing the remaining IND-enabling studies that will support the IND submission and transition into Phase I and Phase II clinical studies.
"We are undergoing a mental health epidemic, with millions suffering from conditions like PTSD with no current therapeutics on the market to help. We believe that NeuroDirect(TM) ketamine has the potential to be a life-altering treatment option that will provide profound benefits and relief to patients suffering from PTSD," said Chad Harman, CEO of Psycheceutical. "We thank the FDA for the constructive guidance during our pre-IND meeting. The constructive feedback and direction will allow us to be efficient and systematic towards safely transitioning our novel topical treatment from preclinical studies into a full clinical evaluation."
In written responses to the questions provided by Psycheceutical, the FDA provided guidance on inquiries related to manufacturing, safety/toxicology, pre-clinical efficacy studies, clinical trial design, and the rationale necessary to support subsequent human clinical trials. This feedback supports Psycheceutical with greater clarity on the current requirements needed to file an acceptable IND to initiate Phase I and II clinical trials of NeuroDirect(TM) ketamine.Based upon the historical clinical data for ketamine and the C ompany's preclinical testing planned for NeuroDirect(TM) ketamine in 2023, the Company anticipates filing an IND by the end of 2023. In addition, Psycheceutical intends to pursue accelerated approval through one of the FDA's expedited drug approval programs, such as Breakthrough Therapy, pending the development of preliminary clinical evidence to support such designation.
NeuroDirect(TM) for Non-Systemic DeliveryPsycheceutical's patented NeuroDirect(TM) non-systemic delivery technology is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results, while avoiding the systemic side effects of psychedelic compounds suc h as hallucinations, nausea, vomiting, and toxicity. NeuroDirect(TM) is designed to be administered through telehealth or at home instead of a clinical setting, greatly lowering the cost of care for each patient, ensuring that these life-saving treatments are cheap and available to anyone suffering from mental health disorders or central nervous system diseases.
About Psycheceutical Bioscience, Inc. Psycheceutical Bioscience, Inc. is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and top minds in the psychedelic space, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to any one suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
Forward-Looking Statements:Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availab ility and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," "may," "should," "could," "intend," "estimate," "plan," "anticipate," "expect," "believe," "potential" or "continue," or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
Kaia Roman, VP, Strategy & Communications kaia.roman@psycheceutical.com
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
BWVI NEWS: Psycheceutical Bioscience Inc BWVI:OTC Pink - Current Information
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
GlobeNewswire
12:15 PM ET
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSDTopical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD)GlobeNewswireJanuary 26, 2023MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD).
The provisional patent application describes ketamine formulations for topical administration and related methods of treating PTSD, utilizi ng NeuroDirect(TM) non-systemic drug delivery technology. This delivery system is designed to topically distribute neuro-active compounds to the back of the neck for immediate action on a dense population of brain nerve endings. These novel ketamine formulations, and methods of treatment, are being developed to reduce the side effects caused by prior formulations, such as hallucinations, nausea, lethargy, and toxicity, but more importantly to also reduce pain and symptoms of PTSD.
"PTSD can be a serious mental health disorder, with no known effective therapeutic solutions currently available. Millions of people suffer each year," said Chad Harman, Chief Executive Officer of Psycheceutical. "But there is new hope. This patent application supports Psycheceutical's ongoing drug development plans for its revolutionary NeuroDirect(TM) topical delivery system that we believe has the potential to provide new solutions and treatments for PTSD and other mental health conditions."
PTSD is a common mental health condition affecting hundreds of millions of people worldwide, with symptoms ranging from mild to severe. PTSD is commonly interconnected with other mental health conditions, such as anxiety, depression, and substance abuse disorder. People who suffer from PTSD also have a higher risk of suicide.
"Psycheceutical is driven to provide new hope for this debilitating disorder by employing cutting-edge technologi es for the patients who need it most," said Dr. Julian Bailes, Chief Medical Officer of Psycheceutical. "We look forward to improving current mental health treatments while progressing the capabilities of the psychedelic pharmaceutical category."
NeuroDirect(TM) for Non-Systemic DeliveryPsycheceutical's NeuroDirect(TM) non-systemic delivery technology is protected by several patents and pending applications, and is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results, while avoiding the systemic side effects of psychedelic compounds such as hallucinations, nausea and vomiting. NeuroDirect(TM) is designed to be administered through telehealth or at home instead of a clinical setting, greatly lowering the cost of care for each patient, ensuring that these life-saving treatments are cheap and available to anyone suffering from mental health disorders or central nervous system diseases.
About Psycheceutical Bioscience, Inc. Psycheceutical Bioscience, Inc. is seeking to develop cutting-edge delivery technologies to support and advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and the top minds in the psychedelic space, Psycheceutical is on a mission to develop, improve and commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
Forward-Looking Statements:Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (ii i) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," "may," "should," "could," "intend," "estimate," "plan," "anticipate," "expect," "believe," "potential" or "continue," or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
Kaia Roman, VP, Strategy & Communications kaia.roman@psycheceutical.com
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
HBAN RECORD Quarter: Huntington Bancshares Inc HBAN:NASDAQ
HUNTINGTON BANCSHARES INCORPORATED REPORTS 2022 FOURTH-QUARTER EARNINGS
PR Newswire
7:00 AM ET
Delivers Record Full-Year Net Income and Achievement of Medium-Term Financial Targets
2022 Fourth-Quarter Highlights:
-- Earnings per common share (EPS) for the quarter were $0.42, an increase of $0.03 from the prior quarter. Excluding the after tax impact of Notable Items, adjusted earnings per common share were $0.43.
-- Net interest income increased $58 million, or 4%, from the prior quarter, refl ecting net interest margin expansion of 10 basis points to 3.52% and higher average total loans and leases.
-- Pre-Provision Net Revenue (PPNR) increased $36 million, or 4%, from the prior quarter to $893 million. Excluding Notable Items, adjusted PPNR increased $41 million, or 5%, from the prior quarter to $908 million.
-- Average total loans and leases increased $1.9 billion, or 2%, from the prior quarter to $118.9 billion. Excluding the decrease in PPP loans, average total loans and leases increased $2.1 billion, or 2%, from the prior quarter.
-- Average total commercial loans and leases increased $1.8 billion, or 3%, and average total consumer loans increased $184 million from the prior quarter.
-- Ending total deposits increased $1.6 billion and average total deposits decreased $336 million from the prior quarter.
-- Net charge-offs of 0.17% of average total loans and leases for the quarter.
-- Nonperforming assets have declined six consecutive quarters.
-- Allowance for credit losses (ACL) of $2.3 billion, or 1.90%, of total loans and leases at quarter end.
-- Common Equity Tier 1 (CET1) risk-based capital ratio increased to 9.44%, within our 9% to 10% operating guideline.
-- Board of Directors approved a $1 billion share repurchase authorization for the next eight quarters.
2022 Full-Year Highlights Compared to Full-Year 2021:
-- Earnings per common share (EPS) for the year were $1.45, an increase of $0.55. Excluding after tax impact of Notable Items, adjusted earnings per common share were $1.50.
-- PPNR increased $1.4 billion, or 88%, from the prior year to $3.1 billion. Excluding Notable Items, adjusted PPNR increased $0.8 billion, or 36%, to $3.2 billion, r eflecting the benefits of the TCF Financial Corporation ("TCF") acquisition and organic growth.
-- Net income attributable to Huntington Bancshares Incorporated increased 73% to $2.2 billion.
-- Maintained solid credit quality with net charge-offs of 0.11% of average total loans and leases.
-- Completed the cost synergy program related to the acquisition of TCF.
-- Delivered on efficiency strategies through the continued optimization of the branch network by closing 63 branches during the year and announcement of an additional 31 branch closures to occur in the first quarter of 2023.
-- Successfully implemented additional Fair Play enhancements and expanded expertise and capabilities with the acquisitions of Capstone Partners and Torana.
Huntington Bancshares Incorporated (Nasdaq: HBAN) reported net income for the 2022 fourth quarter of $645 million, or $0.42 per common share, an increase of $244 million, or $0.16 per common share from the year-ago quarter.
https://mma.prnewswire.com/media/1840939/Huntington_Bank_Logo.jpg
Return on average assets was 1.41%, return on average common equity was 16.0%, return on average tangible common equity (ROTCE) was 26.0%.
CEO Commentary:
"We are very pleased with our outstanding financial performance for the fourth quarter which included the fourth consecutive quarter of record PPNR," said Steve Steinour, chairman, president and CEO. "The year was marked by the successful execution of key strategic initiatives and acquisition synergies which further expanded our capabilities and supported the achievement of our medium-term financial targets.
"Record full-year PPNR was driven by higher net interest income and noninterest income, along with disciplined expense management. We delivered broad-based loan growth and continued to grow our high quality deposit base over the course of the year. Strategic areas of focus for fee income also expanded, with capital markets achieving record revenue, withstrong core performance plus the acquisition of Capstone. We completed the cost synergies from TCF, which provided additional scale and efficiencies in numerous areas across the bank, even as we continued to invest in key revenue-producing initiatives.
"Credit continued to perform very well, with full-year net charge-offs of 11 basis points, well below our through-the-cycle target, and nonperforming assets declined for the sixth consecutive quarter.
"Given our growing capital base, and robust profitability profile, we are pleased to ann ounce a share repurchase program as we enter the new year, consistent with our capital priorities. While we recognize the uncertain economic outlook on the horizon, we enter 2023 from a position of strength. Huntington has never been better positioned to navigate through various economic scenarios, with solid capital levels and top tier reserve profile guided by our aggregate moderate-to-low risk appetite through the cycle. Business line momentum continues in the new year and we are driving value for shareholders."
The fourth quarter 2022 earnings materials, including the detailed earnings press release, quarterly financial supplement, and conference call slide presentation, are available on the Investor Relations section of Huntington's website,http://huntington.com/ In addition, the financial results will be furnished on a Form 8-K that will be available on the Securities and Exchange Commission website at www.sec.gov.
Conference Call / Webcast Information
Huntington's senior management will host an earnings conference call on January20, 2023, at 9:00a.m. (Eastern Time). The call may be accessed via a live Internet webcast at the Investor Relations section of Huntington's website, www.huntington.com, or through a dial-in telephone number at (877)407-8029; Conference ID #13734972. Slides will be available in the Investor Relations section of Huntington's website about an hour prior to the call. A replay of the webcast will be archived in the Investor Relations section of Huntington's website. A telephone replay will be available approximately two hours after the completion of the call through January 28, 2023 at (877)660-6853 or (201)612-7415; conference ID #13734972.
Please see the 2022 Fourth Quarter Quarterly Financial Supplement for additional detailed financial performance metrics. This document can be found on the Investor Relations section of Huntington's website, http://www.huntington.com.
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
BWVI NEWS:Psycheceutical Bioscience Inc BWVI:OTC Pink - Current Information
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
GlobeNewswire
2:05 PM ET
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical OfficerRenowned neurosurgeon to oversee the development of breakthrough psychedelic therapeuticsGlobeNewswireJanuary 10, 2023MIAMI, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc.(OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, today announced that Dr. Julian Bailes has accepted the role of Chief Medical Officer and will also join the company's Board of Directors. Bailes will continue to assist in the strategy, direction, and execution of the company's clinical and technological development of its patented dosing technologies, with the goal of providing the safe and effective delivery of psychedelic pharmaceutical compounds.
"Psycheceutical's Board believes that given his extensive expertise in both clinical care and research, Dr. Bailes is ideally suited to oversee the company's medical affairs as we prepare to initiate clinical trials for our novel drug delivery systems later this year," said Chad Harman, CEO of Psychececutical.
Bailes is an esteemed leader in the fields of neurosurgery and traumatic brain injuries. His expertise in the understanding of CTE was showcased in the 2015 film "Concussion," starring Will Smith, where Bailes was portrayed by actor Alec Baldwin. He is the Chairman of the Department of Neurosurgery, Co-Director of the Neurological Institute at NorthShore University Health System, and Clinical Professor of N eurosurgery at the University of Chicago Pritzker School of Medicine. Bailes is also a Senior Advisor to the NFL Head, Neck, and Spine Committee and a member of the NFLPA Mackey-White Health and Safety Committee and the Chair of the Medical Advisory Board of Pop Warner Football, Inc.
"I've been continually impressed by the assemblage of Psycheceutical's first-class team, the opportunities they have identified, as well as the progress they've made in furthering their brain drug development technology in such a short time," said Dr. Julian Bailes, Chief Medical Officer of Psycheceutical. "Disease and mental health states such as depression, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), post-traumatic stress disorder (PTSD), and anxiety could significantly be improved upon wit h further advances in brain delivery technology. I decided to further my involvement by joining the Board of Directors to help advance this critical technology as soon as possible to hopefully improve the mental health crisis we're experiencing around the world."
As Chief Medical Advisor for Psycheceutical, Bailes will continue his role overseeing the company's Medical Advisory Board, a team of top medical specialists guiding the research and development of the company's next-generation dosing and delivery technology. The Medical Advisory Board works in tandem with the company's scientific team in identifying and reviewing outstanding molecules to bring through the drug discovery and development process to clinical application.
With his addition to the Board of Directors, Bailes will provide strategic focus on advancing the company's mission to bring its innovative drug delivery technologies to market, ensure the company is adhering to the policies and regulations set forth by the DEA and FDA, and offer guidance on future partnerships and the acquisition of intellectual property.
About Psycheceutical Bioscience, Inc. Psycheceutical Bioscience, Inc. is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and the top minds in the psychedelic space, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
Forward-Looking Statements:Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limite d to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," "may," "should," "could," "intend," "estimate," "plan," "anticipate," "expect," "believe," "potential" or "continue," or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Mornin All~~!!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!